THIS COMPONENT IS ENTITLED THE GENOME ENGINEERING AND iPSC CENTER ABSTRACT GEiC Summary Statement/Abstract Genome engineering is a rapidly evolving field that enables the manipulation of complex genomes. Genome engineering uses custom endonucleases to create targeted double-strand breaks in genomic DNA. The repair of these DNA breaks by the natural cellular repair machinery can lead to targeted, user-defined genomic modifications enabling unprecedented abilities to study genetic variation and to manipulate cells for research and therapeutic purposes. These modifications can be anything from a targeted gene knockout to the precise change of a single nucleotide. For example, isogenic cell lines differing only by a single disease-associated variant (single nucleotide mutation, insertion or deletion) can be produced. Additionally, by injecting RNA encoding these custom endonucleases into a single-cell mouse embryo, investigators can rapidly produce genetically modified mice with the aforementioned genome manipulations. The system can also be used to produce other modified organisms (e.g. zebrafish, Drosophila, rats). Induced pluripotent stem cells (iPSCs) have the potential to develop into all tissues and organs of the human body, and therefore open new research avenues for disease modeling. Here, skin fibroblasts or renal epithelial cells from urine can be obtained from patients and reprogrammed into iPSCs, which in turn can be differentiated into a specific cell type to study pathogenesis associated with genetic mutations. Recent advances in genome editing using TALEN and CRISPR-based nucleases can be employed to ?repair? the disease mutation in the iPSC line generated for a specific patient. Alternatively these techniques allow rapid and facile introduction of disease-associated mutations into `normal' iPSCs so that a variety of disorders can be modeled without direct access to the patient's cells that harbor the specific mutation. This technology thus provides the ability to generate cells harboring a number of disease-causing mutations for screening purposes as well as cells that differ only at a single nucleotide for control purposes. To implement both the genome editing and iPSC technologies for use by biological and clinical scientists, we established the Genome Engineering and iPSC Center (GEiC) at Washington University with the goal of speeding scientific discovery through the rapid and precise modification of genomes. The GEiC is directed and staffed with scientists that together have over 25 years of genome engineering experience and 20 years of stem cell experience.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA091842-14
Application #
8928321
Study Section
Subcommittee G - Education (NCI)
Project Start
2001-08-02
Project End
2020-07-31
Budget Start
2015-08-01
Budget End
2016-07-31
Support Year
14
Fiscal Year
2015
Total Cost
$143,863
Indirect Cost
$49,527
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Olfson, Emily; Bloom, Joseph; Bertelsen, Sarah et al. (2018) CYP2A6 metabolism in the development of smoking behaviors in young adults. Addict Biol 23:437-447
Betleja, Ewelina; Nanjundappa, Rashmi; Cheng, Tao et al. (2018) A novel Cep120-dependent mechanism inhibits centriole maturation in quiescent cells. Elife 7:
Chen, Li-Shiun; Horton, Amy; Bierut, Laura (2018) Pathways to precision medicine in smoking cessation treatments. Neurosci Lett 669:83-92
Celik, Hamza; Koh, Won Kyun; Kramer, Ashley C et al. (2018) JARID2 Functions as a Tumor Suppressor in Myeloid Neoplasms by Repressing Self-Renewal in Hematopoietic Progenitor Cells. Cancer Cell 34:741-756.e8
Kabir, Ashraf Ul; Lee, Tae-Jin; Pan, Hua et al. (2018) Requisite endothelial reactivation and effective siRNA nanoparticle targeting of Etv2/Er71 in tumor angiogenesis. JCI Insight 3:
Hirbe, Angela C; Jennings, Jack; Saad, Nael et al. (2018) A Phase II Study of Tumor Ablation in Patients with Metastatic Sarcoma Stable on Chemotherapy. Oncologist 23:760-e76
Jenkins, Wiley D; Gilbert, David; Chen, Li-Shiun et al. (2018) Finding paths with the greatest chance of success: enabling and focusing lung cancer screening and cessation in resource-constrained areas. Transl Lung Cancer Res 7:S261-S264
Cherian, Mathew A; Olson, Sydney; Sundaramoorthi, Hemalatha et al. (2018) An activating mutation of interferon regulatory factor 4 (IRF4) in adult T-cell leukemia. J Biol Chem 293:6844-6858
Smith, Lee; Ae Lee, Jung; Mun, Junbae et al. (2018) Levels and patterns of self-reported and objectively-measured free-living physical activity among prostate cancer survivors: A prospective cohort study. Cancer :
Burclaff, Joseph; Mills, Jason C (2018) Plasticity of differentiated cells in wound repair and tumorigenesis, part II: skin and intestine. Dis Model Mech 11:

Showing the most recent 10 out of 1244 publications